Abstract
Hepatitis B virus surface antigen (HBsAg) is a complex macromolecular particle composed of glycoproteins and lipids. The latter, representing 25% of the particle mass, are of host origin and determine the solubility, stability, and, indirectly, B-cell immunogenicity of HBsAg. HBsAg is a T-cell-dependent immunogen that does not elicit a detectable humoral immune response in 5% of HBsAg vaccine recipients and in most subjects suffering from chronic hepatitis B. We investigated the influence of the lipid content on the antigenicity of the particle. Lipids were partially removed from HBsAg by treatment with beta-D-octyl glucoside and density centrifugation. Sham treatment consisted of density centrifugation of HBsAg only. We compared the in vitro proliferative responses of established T-cell lines and nonfractionated peripheral blood mononuclear cells (PBMC) from HBsAg vaccinees and chronic HBV patients when stimulated with partially delipidated HBsAg, untreated HBsAg, or sham-treated HBsAg. In all experiments, delipidated HBsAg turned out to be 10 to 100 times more antigenic than its untreated or sham-treated counterpart. Remarkably, PBMC from vaccine nonresponders or chronic HBV patients displayed a proliferative response towards...Continue Reading
References
Jan 1, 1992·Intervirology·H J StirkC R Howard
Feb 1, 1992·The Journal of Experimental Medicine·M S KruskallD Marcus-Bagley
Feb 1, 1990·The Biochemical Journal·F GavilanesD L Peterson
Feb 1, 1989·Journal of Virology·E Celis, R W Karr
Jan 1, 1988·Electrophoresis·J Heukeshoven, R Dernick
May 1, 1971·The Journal of Infectious Diseases·C Y Kim, D M Bissell
Mar 5, 1981·Nature·J SkellyA J Zuckerman
Jan 1, 1984·The Journal of Experimental Medicine·D R MilichF V Chisari
Feb 15, 1995·Biochimica Et Biophysica Acta·J Gómez-GutiérrezF Gavilanes
Jan 1, 1995·Research in Virology·N SonveauxJ M Ruysschaert
Jul 1, 1994·Vaccine·G Leroux-RoelsJ Pêtre
Jan 1, 1995·Vaccine·J M BrewerJ Alexander
Aug 1, 1995·Journal of Protein Chemistry·N SonveauxR Brasseur
Jan 1, 1995·Intervirology·A BertingW H Gerlich
Aug 1, 1996·Vaccine·D J West, G B Calandra
Jul 1, 1997·Tissue Antigens·A B McDermottJ A Madrigal
Nov 19, 1997·Vaccine·G Leroux-RoelsA Safary
Nov 19, 1997·Vaccine·G Leroux-RoelsA Safary
Aug 7, 1998·Tissue Antigens·I DesombereG Leroux-Roels
Sep 29, 1999·Vaccine·D DiminskyY Barenholz
Dec 21, 2000·Clinical and Experimental Immunology·I DesombereG Leroux-Roels
Sep 11, 2003·Autoimmunity Reviews·David R Milich, Geert G Leroux-Roels
Mar 2, 2005·Annals of Internal Medicine·Brian J McMahonHarold S Margolis
Mar 2, 2005·Nature Reviews. Immunology·Barbara Rehermann, Michelina Nascimbeni
Mar 15, 2005·Clinical and Experimental Immunology·I DesombereG Leroux-Roels
May 26, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Andrew GodkinAdrian V S Hill
Citations
Jan 22, 2010·Archives of Virology·R A A PondéM O Ferro
Jun 21, 2011·Immunopharmacology and Immunotoxicology·Ke OuyangMinghua Shi
Dec 2, 2008·Vaccine·Yong XieDuo Li
Nov 1, 2015·Archives of Biochemistry and Biophysics·Shweta ShahJohn A Howard
Mar 3, 2007·Journal of Controlled Release : Official Journal of the Controlled Release Society·Anil VangalaYvonne Perrie
May 30, 2015·BMC Immunology·Siddhartha MahantyOlivier Garraud
Nov 23, 2007·Vaccine·Pierre VandepapelièreUNKNOWN Therapeutic HBV Vaccine Group of Investigators
Apr 22, 2016·Journal of Virology·Nadine van MontfoortAndrea M Woltman
Aug 11, 2019·Archives of Virology·Robério Amorim de Almeida Pondé
Jul 28, 2019·Journal of Pharmaceutical Sciences·Monika KauravRavi Shankar Pandey